Your browser doesn't support javascript.
loading
Increasing global accessibility to high-level treatments for cervical cancers.
Chargari, C; Arbyn, M; Leary, A; Abu-Rustum, N R; Basu, P; Bray, F; Chopra, S; Nout, R; Tanderup, K; Viswanathan, A N; Zacharopoulou, C; Soria, J C; Deutsch, E; Gouy, S; Morice, P.
Affiliation
  • Chargari C; Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Inserm U-1030, Université Paris-Saclay, Le Kremlin-Bicêtre, France. Electronic address: cyrus.chargari@gustaveroussy.fr.
  • Arbyn M; Unit Cancer Epidemiology - Belgian Cancer Centre, Brussels, Belgium.
  • Leary A; Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Abu-Rustum NR; Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, United States; European Society of Gynecological Oncology, Geneva, Switzerland.
  • Basu P; Early Detection, Prevention & Infection Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.
  • Bray F; Cancer Surveillance Branch, International Agency for Research on Cancer, UK.
  • Chopra S; Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Homi Bhabha National Institute, Maharashtra, India.
  • Nout R; Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands.
  • Tanderup K; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Viswanathan AN; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medicine, Baltimore, MD, United States.
  • Zacharopoulou C; European Parliament, Committee on the Environment, Public Health and Food Safety, France.
  • Soria JC; Governance, Gustave Roussy Cancer Campus, Villejuif, France; Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Deutsch E; Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Inserm U-1030, Université Paris-Saclay, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Gouy S; Inserm U-1030, Université Paris-Saclay, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Le Kremlin-Bicêtre, France; Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • Morice P; Inserm U-1030, Université Paris-Saclay, Le Kremlin-Bicêtre, France; European Society of Gynecological Oncology, Geneva, Switzerland; Université Paris-Saclay, Le Kremlin-Bicêtre, France; Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Gynecol Oncol ; 164(1): 231-241, 2022 01.
Article in En | MEDLINE | ID: mdl-34716024
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Health Services Accessibility Type of study: Guideline / Prognostic_studies / Screening_studies Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Uterine Cervical Neoplasms / Papillomavirus Infections / Health Services Accessibility Type of study: Guideline / Prognostic_studies / Screening_studies Limits: Female / Humans Language: En Journal: Gynecol Oncol Year: 2022 Type: Article